Yüklüyor......
FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next?
Patients with intrahepatic cholangiocarcinoma (iCCA) face a highly dismal prognosis, due to late stage diagnosis, the relative chemoresistance of the disease, and an overall limited portfolio of established therapeutic concepts. In recent years, a number of next generation sequencing studies have pr...
Kaydedildi:
| Yayımlandı: | Ther Adv Med Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7498964/ https://ncbi.nlm.nih.gov/pubmed/32983265 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920953293 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|